BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21174088)

  • 1. Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
    Roberson PL; Amro H; Wilderman SJ; Avram AM; Kaminski MS; Schipper MJ; Dewaraja YK
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):874-83. PubMed ID: 21174088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters.
    Roberson PL; Wilderman SJ; Avram AM; Kaminski MS; Schipper MJ; Dewaraja YK
    Cancer Biother Radiopharm; 2014 Feb; 29(1):26-33. PubMed ID: 24102174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
    Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
    J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
    Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
    J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
    Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
    Dewaraja YK; Schipper MJ; Roberson PL; Wilderman SJ; Amro H; Regan DD; Koral KF; Kaminski MS; Avram AM
    J Nucl Med; 2010 Jul; 51(7):1155-62. PubMed ID: 20554734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.
    Rajendran J; Gopal A; Durack L; Fisher D; Press O; Eary J
    Cancer Biother Radiopharm; 2004 Dec; 19(6):738-45. PubMed ID: 15665621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
    Siegel JA; Kroll S; Regan D; Kaminski MS; Wahl RL
    J Nucl Med; 2002 Mar; 43(3):354-63. PubMed ID: 11884495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
    J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
    Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
    J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
    Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 131I-tositumomab.
    Lewington V
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.
    Amro H; Wilderman SJ; Dewaraja YK; Roberson PL
    J Nucl Med; 2010 Apr; 51(4):654-9. PubMed ID: 20237032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.
    Rutar FJ; Augustine SC; Kaminski MS; Wahl RL; Siegel JA; Colcher D
    Clin Lymphoma; 2001 Dec; 2(3):164-72. PubMed ID: 11779293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma.
    Vose JM
    Oncologist; 2004; 9(2):160-72. PubMed ID: 15047920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
    J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
    J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
    Wahl RL
    J Nucl Med; 2005 Jan; 46 Suppl 1():128S-40S. PubMed ID: 15653661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.